<p>The National Cancer Institute's (NCI) Childhood Cancer Data Initiative (CCDI) focuses on the critical need to collect, analyze, and share data to address the burden of cancer in children, adolescents, and young adults (AYAs). The Molecular Characterization Initiative (MCI) will further the CCDI's goals by providing access to better diagnostic tests for pediatric and AYA patients. The molecular characterizations of solid tumors, soft tissue sarcomas, and rare diseases are performed in a CLIA-certified setting as results may be used to screen for and/or confirm clinical trial eligibility, direct treatment, or otherwise contribute to the conduct of the trial. The following molecular characterization assays were performed:</p><ul><li>Tumor/Normal Whole Exome sequencing </li><li>Methylation arrays</li><li>Archer fusion panel </li><li>Deidentified clinical reports</li></ul><p>Note: New data will be added periodically, please check the <a href="https://ccdi.cancer.gov/explore">CCDI Hub Explore</a> site for updates.</p>

Childhood Cancer Data Initiative (CCDI): Molecular Characterization    Initiative

Neoplasms study with OTHER, RNA-Seq + 1 more data on CRDC (5,516 participants)